
    
      This research study is a Phase II clinical trial. Phase II clinical trials test the safety
      and effectiveness of an investigational intervention to learn whether the intervention works
      in treating a specific disease. "Investigational" means that the intervention is being
      studied.

      Eribulin works by interfering with cancer cell division, growth, and spread.

      The goal of this research study is to evaluate inflammatory breast cancer's response to
      treatment with eribulin followed by AC chemotherapy (Cohort A) and also the response to
      treatment with AC followed by Eribulin (Cohort B) when given as a preoperative chemotherapy
      treatment for participants with HER2 negative inflammatory breast cancer.
    
  